Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.

Détails

ID Serval
serval:BIB_D9F47C808CCB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
Périodique
Neurology
Auteur(s)
Rascol O., Montastruc J.L., Senard J.M., Demonet J.F., Simonetta M., Rascol A.
ISSN
0028-3878 (Print)
ISSN-L
0028-3878
Statut éditorial
Publié
Date de publication
1988
Peer-reviewed
Oui
Volume
38
Numéro
9
Pages
1387-1391
Langue
anglais
Notes
Publication types: Clinical Trial ; Controlled Clinical Trial ; Journal ArticlePublication Status: ppublish
Résumé
We investigated the influence of 2 weeks of treatment with deprenyl on the acute effect of a single dose of 200 mg of L-dopa in a double-blind cross-over placebo-controlled trial in 16 parkinsonian patients with wearing-off phenomena. Deprenyl induced no significant benefit in the duration or the maximal improvement of L-dopa's effect. Moreover, deprenyl treatment did not improve the patient's motor status.
Mots-clé
Aged, Animals, Clinical Trials as Topic, Double-Blind Method, Drug Interactions, Female, Humans, Levodopa/administration & dosage, Levodopa/therapeutic use, Male, Middle Aged, Parkinson Disease/drug therapy, Phenethylamines/administration & dosage, Placebos, Selegiline/administration & dosage, Selegiline/therapeutic use
Pubmed
Web of science
Création de la notice
24/03/2013 15:40
Dernière modification de la notice
03/03/2018 21:53
Données d'usage